Likewise, patients receiving first- through fourth-line therapy for germline BRCA1/2 mutation-associated HER2-negative BC in the phase-3 EMBRACA trial were randomly assigned to receive talazoparib or chemotherapy [115]. Here, ERBB2 is linked to breast cancer.